ClinicalTrials.gg
CompletedNCT01147003Updated Dec 17, 2020

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

A Phase 2 interventional study of Investigational new drug, company code: BGG492 and Placebo in Partial Onset Seizures, sponsored by Novartis. Completed at 51 sites in 10 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will assess the efficacy and safety of BGG492 as adjunctive treatment in patients with partial onset seizures.

02

Conditions studied

  • Partial Onset Seizures

Keywords

  • Seizure frequency
  • nervous system diseases
  • brain diseases
  • neurologic manifestations
  • adjunctive treatment
  • AEDs
  • antiepileptic drug
03

In context

Nervous System Diseases

758 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.

This study's enrollment of 93 is above the median of 55 across 496 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients ≥ 50 kg (110 lb) of weight.
  • A diagnosis of epilepsy (≥ 2 years prior to screening) with partial seizures with or without secondarily generalized seizures.
  • Uncontrolled partial seizures despite having been treated with at least two different antiepileptic drugs (AEDs) within the last 2 years prior to screening.
  • At least 4 partial seizures during the 4-week baseline period and at least 4 partial seizures during the 4 weeks prior to the baseline period.
  • Cohort 1 patients must be receiving stable treatment with 1 or a maximum of 2 AEDs.Cohort 2 patients must be receiving stable treatment with 1, 2, or 3 AEDs.

Exclusion criteria

Exclusion Criteria:

  • Presence of only non-motor simple partial seizures.
  • History of psychogenic seizures.
  • Absences, myoclonic seizures e.g. in the context of primary generalized epilepsy.
  • Previous history of Lennox-Gastaut syndrome.
  • Status epilepticus or seizure clusters, according to the judgement of the investigator, occurring within 52 weeks prior to randomization.
  • Pregnant or nursing (lactating) women.

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    BGG492 low dose

    Drug: Investigational new drug, company code: BGG492

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    BGG492 high dose

    Drug: Investigational new drug, company code: BGG492

Interventions

06

What researchers measure

Primary outcomes

  1. To detect a dose-response by measuring the percent change in seizure frequency of BGG492 from baseline to maintenance period.

    Time frame: 28 days

Secondary outcomes

  1. To evaluate the efficacy of BGG492 compared to placebo as a change in seizure frequency from baseline period to maintenance period.

    Time frame: 28 days

  2. Responder rate: analysis of patients with a 50% or greater reduction in seizure frequency of BGG492 during the maintenance period.

    Time frame: 28 days

  3. Safety and tolerability of BGG492 compared to placebo.

    Time frame: 12 weeks

  4. Pharmacokinetic profile of BGG492

    Time frame: 10 weeks

07

Study locations

51 sites
  • Barrow Neurological Clinics at St. Joseph's Hospital and MC
    Phoenix, Arizona 85013, United States
  • Center for Neurosciences
    Tucson, Arizona 85718, United States
  • Clinical Trials, Inc.
    Little Rock, Arkansas 72205, United States
  • Medical Center of the Rockies
    Loveland, Colorado 80538, United States
  • AMO Corporation
    Tallahassee, Florida 32308, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Investigative Site - Private Practice
    Ocean Springs, Mississippi 39564, United States
  • St.John's Research Institute, Inc
    Springfield, Missouri 65804, United States
  • Renown Institute for Neurosciences
    Reno, Nevada 89521, United States
  • NJ to Capital Health in Hamilton
    Somerset, New Jersey 08873, United States
  • Princeton and Rutgers Neurology
    Somerset, New Jersey 08873, United States
  • NYU Comprehensive Epilepsy Center
    New York, New York 10016, United States
  • Thomas Jefferson University, Dept. of Psychiatry & Neurology
    Philadelphia, Pennsylvania 19107, United States
  • Neurological Clinic of Texas
    Dallas, Texas 75230, United States
  • Novartis Investigative Site
    Sofia, 1113, Bulgaria
  • Novartis Investigative Site
    Bernau, 16321, Germany
  • Novartis Investigative Site
    Bielefeld, 33617, Germany
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Kehl-Kork, 77694, Germany
  • Novartis Investigative Site
    Marburg, Germany
  • Novartis Investigative SIte
    Regensburg, Germany
  • Novartis Investigative Site
    Tuebingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, Germany
  • Novartis Investigative Site
    Budapest, 1096, Hungary
  • Novartis Investigative Site
    Kecskemet, 6000, Hungary
  • Novartis Investigative Site
    Szombathely, 9700, Hungary
  • Novartis Investigative Site
    Bologna, 40123, Italy
  • Novartis Investigative Site
    Catanzaro, 88100, Italy
  • Novartis Investigative Site
    Firenze, 50143, Italy
  • Novartis Investigative Site
    Milano, 20142, Italy
  • Novartis Investigative Site
    Milano, 40123, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Venezia, 30122, Italy
  • Novartis Investigative Site
    Seoul, 110-744, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 120-752, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 135-710, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 738-736, Korea, Republic of
  • Novartis Investigative Site
    Gdansk, 80-303, Poland
  • Novartis Investigative Site
    Krakow, 31-209, Poland
  • Novartis Investigative Site
    Warsaw, 02-957, Poland
  • Novartis Investigative Site
    Banska Bystrica, 975 17, Slovakia
  • Novartis Investigative Site
    Bratislava, Slovakia
  • Novartis Investigative Site
    Kosice, 041 90, Slovakia
  • Novartis Investigative Site
    Aarau, 5001, Switzerland
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Zuerich, 8008, Switzerland
  • Novartis Investigative Site
    Changhua, Taiwan
  • Novartis Investigative Site
    Kaohsiung, Taiwan
  • Novartis Investigative Site
    Lin-ko, 33305, Taiwan
  • Novartis Investigative Site
    Taipei, 112, Taiwan
  • Novartis Investigative Site
    Taipei, Taiwan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2010
First posted
Jun 22, 2010
Start
Jun 2010
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results delay requested
Feb 18, 2013
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01147003
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
Jun 2010
Primary completion
Sep 2011
Completion
Sep 2011
Last update
Dec 17, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Drugs, Investigational · Selurampanel

Start the discussion